Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  JACC. Heart failure

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jchf.2017.08.004PMID 29032139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry

  2017cited by this paper
• Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes

  2017cited by this paper
• Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial

  2017cited by this paper
• Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease

  2017cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

  2016cited by this paper
• Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial".

  2015cited by this paper
• Dipeptidyl peptidase‐4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction

  2015cited by this paper
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

  2014cited by this paper
• DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

  2012cited by this paper
• The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta‐analysis of randomized clinical trials

  2012cited by this paper
• Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus

  2011cited by this paper
• Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

  2011cited by this paper
• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

  2010cited by this paper
• Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease.

  2009cited by this paper
• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

  2008cited by this paper
• Diabetes, left ventricular systolic dysfunction, and chronic heart failure.

  2008cited by this paper
• A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

  2007influential reference
• Ventricular remodeling in heart failure: a credible surrogate endpoint.

  2003cited by this paper
• Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

  2000cited by this paper
• Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

  2000cited by this paper
• Left Ventricular Volume from Paired Biplane Two‐dimensional Echocardiography

  1979cited by this paper

• Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis

  2025cites this paper
• Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis

  2025cites this paper
• Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis

  2025influential citation
• Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view.

  2025cites this paper
• Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis

  2025cites this paper
• Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors

  2025cites this paper
• Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis

  2024cites this paper
• Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure

  2024cites this paper
• Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial

  2024cites this paper
• DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment.

  2024cites this paper
• Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

  2024cites this paper
• Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes

  2023influential citation
• Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure

  2023cites this paper
• Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up

  2023cites this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cites this paper
• Simplifying Type 2 DM Care with Linagliptin: A Position Paper.

  2023cites this paper
• Comparison of Composition, Free-Radical-Scavenging Capacity, and Antibiosis of Fresh and Dry Leave Aqueous Extract from Michelia shiluensis

  2023cites this paper
• Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus.

  2023cites this paper
• Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review

  2023cites this paper
• Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism

  2023cites this paper
• A review of current key guidelines for managing high‐risk patients with diabetes and heart failure and future prospects

  2023cites this paper
• Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy

  2023cites this paper
• Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association

  2023cites this paper
• Safety and cardiometabolic efficacy of novel antidiabetic drugs

  2023cites this paper
• A kardiovaszkuláris kockázat, a DPP-4-gátlók, a vércukor-variabilitás és az autonóm neuropathia potencális összefüggései

  2023cites this paper
• Cardio‐renal‐metabolic disease in primary care setting

  2023cites this paper
• Hubungan Efikasi Diri dengan Perawatan Kaki pada Pasien Diabetes Mellitus di Ruang Poli Penyakit Dalam RSD Balung Jember

  2023cites this paper
• Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4

  2023cites this paper
• Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes

  2023cites this paper
• Drug-induced cardiac toxicity and adverse drug reactions, a narrative review.

  2023cites this paper
• Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.

  2023cites this paper
• Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI

  2023cites this paper
• Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia

  2022cites this paper
• The need for adjusting experimental models to meet clinical reality.

  2022cites this paper
• Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes

  2022cites this paper
• Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes

  2022cites this paper
• Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

  2022cites this paper
• Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.

  2022cites this paper
• Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.

  2022cites this paper
• The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease.

  2022cites this paper
• Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

  2022cites this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2022cites this paper
• Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure

  2022cites this paper
• Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.

  2022cites this paper
• Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure.

  2022cites this paper
• Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials

  2022cites this paper
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2022cites this paper
• Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

  2022cites this paper
• Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting

  2022cites this paper
• Pharmacotherapy of type 2 diabetes: An update and future directions.

  2022cites this paper
• Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction

  2022cites this paper
• Effects of DPP-4 inhibitors on brain natriuretic peptide, neuropeptide Y, glucagon like peptide-1, substance P levels and global longitudinal strain measurements in type 2 diabetes mellitus patients

  2022cites this paper
• Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.

  2022cites this paper
• Paracrine signal emanating from stressed cardiomyocytes aggravates inflammatory microenvironment in diabetic cardiomyopathy

  2022cites this paper
• Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

  2021cites this paper
• Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction?

  2021cites this paper
• Diabetes Mellitus

  2021cites this paper
• Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

  2021cites this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2021cites this paper
• Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement

  2021cites this paper
• Association of Renal and Cardiovascular Safety With DPP‐4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease

  2021cites this paper
• New antidiabetic therapy and HFpEF: light at the end of tunnel?

  2021cites this paper
• The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

  2021cites this paper
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2021cites this paper
• Diabetes Mellitus and Heart Failure: A Consensus Statement

  2021cites this paper
• The effects of antidiabetic agents on heart failure

  2021cites this paper
• Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.

  2021cites this paper
• CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.

  2021cites this paper
• Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging

  2021cites this paper
• Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype

  2021cites this paper
• Optimal Type 2 Diabetes Mellitus Management and Active Ageing

  2021cites this paper
• Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

  2021cites this paper
• Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD)

  2020cites this paper
• Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

  2020cites this paper
• Comorbidity in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Cluster analysis of the RICA registry. Opportunities for improvement.

  2020cites this paper
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis

  2020cites this paper
• Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction

  2020cites this paper
• DPP4 Inhibition, NPY1-36, PYY1-36, SDF-1α, and a Hypertensive Genetic Background Conspire to Augment Cell Proliferation and Collagen Production: Effects That Are Abolished by Low Concentrations of 2-Methoxyestradiol

  2020cites this paper
• A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes

  2020cites this paper
• Management of type 2 diabetes: consensus of diabetes organizations

  2020cites this paper
• Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

  2020cites this paper
• Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

  2020cites this paper
• Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.

  2020cites this paper
• Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2

  2020cites this paper
• Reappraisal on pharmacological and mechanical treatments of heart failure

  2020cites this paper
• Consensus document: management of heart failure in type 2 diabetes mellitus

  2020cites this paper
• Impact of Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control and Cardiovascular Safety with Adherence: An Overview

  2020cites this paper
• Comorbidity in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Cluster analysis of the RICA registry. Opportunities for improvement

  2020cites this paper
• The efficacy and safety of Dipeptyl Peptidase-4 inhibitors compared to other Oral glucose-lowering medications in the treatment of type 2 diabetes.

  2020cites this paper
• Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

  2020cites this paper
• The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.

  2020cites this paper
• The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments.

  2020cites this paper
• Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function

  2020cites this paper
• 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

  2020cites this paper
• Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection

  2020cites this paper
• Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist

  2020cites this paper
• Patient-Centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-Analysis and Trial Sequential Analysis.

  2020cites this paper
• Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.

  2020cites this paper
• New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis

  2020cites this paper
• Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

  2020cites this paper